EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Secondary Biologic Failure in Moderate‐to‐Severe Plaque Psoriasis: Retrospective Multivariable Analysis in China

Ying Zhou, Weiquan Chen, Litian Zhang, Kun Zhong

Dermatologic Therapy · 2026-01 · 2026 (1)

DOI: 10.1155/dth/7576221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 24.07.2026. Verfasst von Ying Zhou und 3 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Secondary failure (SF) to biologic therapies (BTs), defined as the loss of efficacy after initial treatment success, poses a significant challenge to moderate‐to‐severe plaque psoriasis treatment. While SF predictors have been explored in Western populations, data remain scarce among Chinese patients.

Objectives

To identify demographic, clinical, and treatment‐related predictors of SF to BTs in Chinese patients with moderate‐to‐severe plaque psoriasis using real‐world registry data.

Methods

This multicenter retrospective cohort study used China Psoriasis Center Register data. Kaplan–Meier survival analysis and multivariate Cox regression were applied to assess predictors of SF.

Results

Among 409 eligible patients (mean age: 46.2% and 69.4% male), 46 (11.2%) experienced SF during follow‐up (median = 166 days, interquartile range 93–365 days). Most patients received anti–IL‐17A therapy, particularly secukinumab. Multivariate analysis confirmed independent risks for advancing age (adjusted HR [aHR] = 1.02 per year, 95% CI: 1.00–1.05, p = 0.037) and lower DLQI (aHR = 0.95 per unit increase, 95% CI: 0.91–1.00, p = 0.046); first‐time use remained protective (aHR = 0.48, 95% CI: 0.26–0.89, p = 0.021). Sex, smoking, and metabolic comorbidities showed no significant associations.

Conclusions

Advancing age, prior BT use, and lower baseline DLQI scores may independently predict SF. First‐line BT initiation and baseline quality‐of‐life impairment may be associated with improved treatment durability. Vigilant monitoring in high‐risk subgroups and baseline quality‐of‐life assessments are crucial.

Zitieren

APA

Zhou, Y., Chen, W., Zhang, L., & Zhong, K. (2026). Secondary Biologic Failure in Moderate‐to‐Severe Plaque Psoriasis: Retrospective Multivariable Analysis in China. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/7576221

Vancouver

Zhou Y, Chen W, Zhang L, Zhong K. Secondary Biologic Failure in Moderate‐to‐Severe Plaque Psoriasis: Retrospective Multivariable Analysis in China. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/7576221

BibTeX
@article{Zhou2026,
  author = {Zhou, Ying and Chen, Weiquan and Zhang, Litian and Zhong, Kun},
  title = {Secondary Biologic Failure in Moderate‐to‐Severe Plaque Psoriasis: Retrospective Multivariable Analysis in China},
  journal = {Dermatologic Therapy},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/dth/7576221}
}
Kostenlos starten →